Rituximab after autologous stem cell transplantation enhances survival of B-cell lymphoma patients: a meta-analysis and systematic review

Transplantation Proceedings
G HeS He

Abstract

Numerous studies have demonstrated the efficacy of rituximab before autologous stem cell transplantation (ASCT) for the treatment of B-cell non-Hodgkin lymphoma, but the few studies on rituximab treatment after ASCT have not established conclusively the clinical benefits of this particular treatment regimen. We conducted a metaanalysis of 3 comparative studies encompassing 407 lymphoma patients treated with rituximab after ASCT. Combined results revealed a significantly higher event-free survival (EFS) in the rituximab-treated (R+) group compared with the R- group (P = .003 at 1 year; P = .03 at 3 years; P = .001 at 4 years). Moreover, the R+ group also demonstrated higher overall survival (OS) and complete remission (CR) rates (P = .0006 and P < .0001, respectively, at 1 year) without a significant increase in adverse events. According to the included articles, there were no differences in CR, overall response, 3-year EFS, or 3-year OS between rituximab-naïve patients and patients previously treated with rituximab before ASCT. Post-ASCT maintenance regimens including rituximab show increased EFS, OS, and CR.

References

Aug 27, 2002·Cytotherapy·S M SmithK van Besien
Jul 26, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Attilio OlivieriPietro Leoni
Mar 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Myron S CzuczmanFrancisco J Hernandez-Ilizaliturri
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corrado TarellaAlessandro Rambaldi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.